# Impact of coenzyme Q10 as an adjuvant therapy to letrozole on spermiogram results and sex hormone levels in Iraqi men with infertility; randomized open label comparative study

**Authors:** Essa Bahauldeen Fadhil, Mohammed Mahmood Mohammed ‎, Ula M. Alkawaz, Isarin Thanaboonyawat, Hayder Fawzi

PMC · DOI: 10.12688/f1000research.131985.1 · 2023-09-01

## TL;DR

This study found that adding coenzyme Q10 to letrozole treatment improved sperm quality and hormone levels in Iraqi men with infertility.

## Contribution

This is the first study to evaluate the adjuvant effect of coenzyme Q10 with letrozole in men with idiopathic oligoasthenoteratozoospermia.

## Key findings

- Combining coenzyme Q10 with letrozole significantly improved sperm concentration, morphology, and motility.
- Testosterone levels and the testosterone/estradiol ratio increased significantly in both groups.
- CoQ10 added significant improvement in most parameters beyond letrozole alone after three months.

## Abstract

Background: Worldwide, infertility affects about 15% of reproductive-age couples. In many cases, infertility can't be treated, however new treatment options with promising value have been involved in recent clinical trials. The aim of this clinical trial was to evaluate the impacts of adding coenzyme Q10 (CoQ10) to letrozole on the results of spermiogram and sex hormone tests in men diagnosed with idiopathic oligoasthenoteratozoospermia (iOAT) syndrome, which is a type of male defective spermatogenesis of unknown etiology.

Methods: This randomized, open-label, parallel two-arm interventional study included 67 adult male patients aged 18-60 years with a confirmed diagnosis of iOAT syndrome recruited from The High Institute for Infertility Diagnosis & Assisted Reproduction Technologies/Nahrain University. Patients were randomly separated into two groups, Group A included 29 patients treated with letrozole 2.5 mg tablet orally twice a week, Group B included 38 patients treated with a combination of letrozole 2.5 mg tablet orally twice a week plus CoQ10 400 mg per day. Both groups completed treatment for three months. Semen samples, serum follicle-stimulating hormone (FSH), estradiol (E
2), and testosterone (T) were analyzed at day one, and at the end of month one, two and three.

Results: Both groups showed that sperm concentration, normal morphology, total sperm count and motility, serum testosterone and FSH levels, and T/E
2 ratio were significantly increased, while estradiol levels significantly decreased after three months of treatment. Seminal fluid volume changed significantly in group A only. In comparing between the two groups, all measured parameters, apart from sperm motility and FSH level, demonstrated a significant difference after three months of treatment, while sperm volume reached significant value after only two months of therapy.

Conclusions: CoQ10 as adjuvant treatment to letrozole effectively improved most of the tested sperm parameters in Iraqi men with iOAT.

Registration:
ClinicalTrials.gov (
NCT05847257, May 6, 2023).

## Linked entities

- **Chemicals:** coenzyme Q10 (PubChem CID 5281915), letrozole (PubChem CID 3902)

## Full-text entities

- **Diseases:** Infertility (MESH:D007246), iOAT syndrome (MESH:D009845), male defective spermatogenesis (MESH:C536875)
- **Chemicals:** CoQ10 (MESH:C024989), testosterone (MESH:D013739), letrozole (MESH:D000077289), E 2 (MESH:D004958), T (MESH:D014316)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11217721/full.md

---
Source: https://tomesphere.com/paper/PMC11217721